Business Summary:
The March Group, LLC currently represents a pioneering health care firm with exclusive rights to a high-growth potential medical concept. The Company holds the patent for landmark counting technology which enables users of metered dose inhalers (MDI’s) a means to improve the efficacy and cost effectiveness of their treatment therapies. The reusable device fits nearly all MDI’s and stores usage data, enabling patients and physicians the ability to monitor progress. The flagship model was granted a 510K by the FDA in 1994; patents are pending for enhanced models. The device fulfills a need created by the growing importance of improved disease management techniques. Furthermore, it is highly valuable in controlling the overall costs and significantly improving the outcome of respiratory treatment therapies. An estimated 50 million patients currently rely on inhaled medications, and that number is growing fast. With simultaneous appeal to a wide variety of market segments, the device holds market potential of approximately 60 million units in the US and over 120 million units abroad. The global market potential ranges from $1.2 billion to $2.4 billion, given a reasonable expected selling price. The Company’s technology has endured almost 15 years of real market experience, over which time it has been continually refined. A strong portfolio of FDA-approved intellectual property and a highly developed business plan – featuring established manufacturing channels – awaits an enthusiastic investor or acquirer.
|
|
|
